PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease

Medicine & Life Sciences

1. Pituitary Adenylate Cyclase-Activating Polypeptide 100%
2. Glycopeptides 86%
3. Vasoactive Intestinal Peptide 80%
4. Parkinson Disease 70%
5. Intercellular Signaling Peptides and Proteins 33%
6. Brain 24%
7. Neuroprotection 21%
8. Dopaminergic Neurons 21%
9. Blood-Brain Barrier 19%
10. Dopamine 17%
11. Receptors, Vasoactive Intestinal Peptide, Type II 17%
12. Receptors, Vasoactive Intestinal Polypeptide, Type I 16%
13. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I 16%
14. Animal Models 14%
15. Drug Stability 14%
16. Secretin 12%
17. CHO Cells 12%
18. Immunomodulation 11%
19. Firearms 11%
20. Microdialysis 11%
21. Therapeutics 10%
22. Surface-Active Agents 10%
23. Drug Development 9%
24. Mass Spectrometry 9%
25. Walking 8%
26. Neurodegenerative Diseases 8%
27. Rodentia 8%
28. Pharmaceutical Preparations 8%
29. Technology 6%
30. Clinical Trials 6%
31. Peptides 6%
32. Inflammation 5%